Open an account

Allogene Therapeutics

ALLO · NASDAQ

$1.33+$0.03 (+2.31%)TodayMarket closed ·
Prev close $1.30

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 150 full-time employees. The company went IPO on 2018-10-11. The firm is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The company is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). The company is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

Employees
150
Headquarters
South San Francisco, California
Listed
Oct 11, 2018
Sector
Health Care
Industry
Biotechnology
Website
allogene.com

ALLO key statistics

Market cap
459.50M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.79M
Volume
4.58M
Open price
$1.30
High today
$1.35
Low today
$1.29
52 Week high
$4.46
52 Week low
$1.04

Allogene Therapeutics (ALLO) at a glance

As of Oct 20, 2026, Allogene Therapeutics (ALLO) shares are priced at $1.33, giving the company a market cap of 459.50M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.29 and $1.35. The current price is 3.1% above the day's low and 1.5% below its high.

Volume so far is 4.58M shares, below the average of 5.79M shares a day.

Over the past year Allogene Therapeutics has ranged from $1.04 to $4.46, and now sits 8% of the way up that range.

Allogene Therapeutics met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.1745.

The average analyst price target is $9.18, 590.2% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 10 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 11 analystsAvg $9.18
Low
$4.04
Now
$1.33
High
$14.70

ALLO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 14.7% on average.

  1. Q3 FY24: reported -$0.32 per share against an estimate of -$0.336
  2. Q4 FY24: reported -$0.28 per share against an estimate of -$0.34
  3. Q1 FY25: reported -$0.28 per share against an estimate of -$0.2955
  4. Q2 FY25: reported -$0.23 per share against an estimate of -$0.279
  5. Q3 FY25: reported -$0.19 per share against an estimate of -$0.2277
  6. Q4 FY25: reported -$0.17 per share against an estimate of -$0.2207
  7. Q1 FY26: reported -$0.18 per share against an estimate of -$0.1942
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.1745

ALLO news

  • Vandana Singh

    Cellectis Pivots to Gene Editing in Major Overhaul

  • Press releaseGlobe Newswire

    Allogene Therapeutics Announces Participation in September Investor Conference

  • Press releaseGlobe Newswire

    Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

  • Press releaseGlobe Newswire

    Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

  • Avi Kapoor

    Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings

Similar companies

Companies in the same industry as Allogene Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.